Go back
“We believe that our mission of advancing healthcare industries and improving health outcomes can only be achieved by recognizing the interdependence between human, animal, and environmental health, also known as the ‘One Health’ concept. As a dedicated health impact investor, all our funds carry the Article 8, 8+ or 9 designation, signifying our commitment to guide healthcare actors in forging resilient, equitable and sustainable healthcare systems.”
Robin Filmer-Wilson is a Partner at ARCHIMED, and a Director of the EURÊKA Foundation, ARCHIMED’s charitable foundation. He currently co-heads the Pharma Services sector team. Robin has a long-standing relationship with the other ARCHIMED partners.
Robin has over 25 years of healthcare private equity experience in the US, Asia, the UK and Europe. Having been born and raised in Hong-Kong, Robin was educated in Europe and the US. He holds a BSFS from Georgetown University and an MBA from INSEAD.
Robin led the transactions of a UK-based occupational health provider, Vita Health, and a France-based nutraceutical company specializing in polyphenols, Fytexia. He previously sat on the Boards of a UK-based pharma strategic consulting firm, Deallus, a Netherlands-based manufacturer of single-use and reusable tapes for operating rooms, SMG, and a US-based manufacturer of wearables for clinical trials, Ametris (formerly ActiGraph).
He currently sits on the Boards of a France-based Contract Research Organization (CRO) and bioanalytical service company, Aliri, a Canada-based Contract Development and Manufacturing Organization (CDMO) and formulation development firm, Corealis, a skincare CDMO specializing in suncare, skincare, and haircare products, Dermapharm, a developer and manufacturer of PET radiopharmaceuticals for diagnosis and research, IRAB, and a CRO specializing in dermatological formulation and clinical testing, Symbio.
PORTFOLIO COMPANIES
